Current trends in molecular diagnostics of chronic myeloid leukemia.
2017
AbstractNearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
104
References
16
Citations
NaN
KQI